Data reported in Clinical Cancer Research support the efficacy of evofosfamide in combination with checkpoint inhibition in advanced, immunologically “cold” tumors.
Read morePress releases
Acquisition Strengthens “Cold” Tumor Targeting Pipeline
• ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.
• Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer.
ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT)
Announcing a $15.5 million grant from Cancer Prevention and Research Institute of Texas (CPRIT) to advance our development of IMGS-001, the dual-specific checkpoint inhibitor and tumor microenvironment remodeling agent.
Read more